10 Year Financial Data of Vertex Pharmaceuticals (VRTX)

79.49 (1y: +28%)

Market Cap	17.24 B	P/E(ttm)
Enterprise Value	16.75 B	P/B	17.37

VRTX- NAS (USA)
Vertex Pharmaceuticals

Currently 1/5

Business Predictability Rank: 1-Star (On Watch)
Back Testing Results:
Average gain of all 1-Star stocks: 1.1% per year.
% of Stocks that are in still loss if held for 10yrs: 45%.
Read more:
What is Predictability Rank?
Performances of real portfolio
Top Ranked Predictable Companies

$79.49

2 Severe Warning Signs 4 Medium Warning Signs

Bookmark

Annual Rates (per share)	10 yrs*	5 yrs*	12 months*
Revenue Growth (%)	14.2	81.1	-18.1
EBITDA Growth (%)	0	0	-227.8
Free Cash Flow Growth (%)	0	0	-40.6
Book Value Growth (%)	13.6	16.4	-18.4

*12-month growth rate is calculated with the per share revenue (EBITDA, FCF, earnings) of the last 12 months over the per share revenue (EBITDA, FCF, earnings) over the previous 12 months. 5-year and 10-year growth rates are calculated with least-square regression based on the 5-year and 10-year numbers.

Trendline:

Export:

Print This Table Print

See this page for the explanation of the data and charts * All numbers are in millions except for per share data

Per Share Data	Annuals											Quarterly
Fiscal Period	Dec03	Dec04	Dec05	Dec06	Dec07	Dec08	Dec09	Dec10	Dec11	Dec12	TTM	Mar12	Jun12	Sep12	Dec12	Mar13

Revenue per Share ($)	0.90	1.31	1.80	1.91	1.54	1.25	0.59	0.72	6.76	7.20	6.63	2.00	1.98	1.57	1.56	1.52
EBITDA per Share	-3.13	-1.59	-1.37	-1.79	-3.04	-3.06	-3.37	-3.32	0.71	0.19	-2.25	0.46	-0.01	0.04	-0.30	-1.98
Free Cashflow per Share	-2.40	-1.97	-2.12	-0.48	-2.21	-1.84	-2.60	-3.36	0.24	0.93	0.57	-0.01	0.49	0.40	0.06	-0.38
Earnings per Share ($)	-2.56	-2.12	-2.28	-1.83	-3.03	-3.27	-3.71	-3.77	0.14	-0.50	-2.37	0.43	-0.31	-0.27	-0.36	-1.43
Book Value per Share	2.50	0.45	2.68	4.47	2.10	1.70	6.33	2.51	3.77	4.71	3.46	4.24	4.91	4.81	4.66	3.46
Month End Stock Price	10.35	10.57	27.67	37.42	23.23	30.38	42.85	35.03	33.21	41.90	54.97	41.01	55.92	55.89	41.90	54.97
Ratios	Annuals											Quarterly
Fiscal Period	Dec03	Dec04	Dec05	Dec06	Dec07	Dec08	Dec09	Dec10	Dec11	Dec12	Latest Q.	Mar12	Jun12	Sep12	Dec12	Mar13

Return on Equity %	-102	-469	-85.00	-40.90	-144	-193	-58.60	-150	3.80	-10.70	-165	39.20	-25.20	-22.40	-30.40	-165
Return on Assets %	-27.20	-30.50	-37.10	-22.40	-65.10	-46.90	-32.80	-43.70	1.30	-3.90	-51.60	15.60	-10.00	-8.40	-11.20	-51.60
Return on Capital - Joel Greenblatt %	--	--	--	--	--	--	--	--	110	0.80	-406	136	-16.40	-1.60	-104	-406
Debt to Equity	1.79	9.45	0.75	0.25	0.07	1.20	0.14	1.07	0.51	0.70	0.99	0.43	0.39	0.39	0.70	0.99

Gross Margin %	95.50	94.50	93.70	94.40	93.00	91.10	86.10	91.10	94.30	81.70	87.00	91.10	72.60	88.50	73.70	87.00
Operating Margin %	-383	-151	-93.20	-106	-211	-264	-603	-486	8.10	0.20	-134	20.90	-2.60	-0.30	-23.20	-134
Net Margin %	-285	-162	-126	-95.60	-197	-262	-630	-526	2.10	-7.00	-93.80	20.90	-15.50	-17.10	-22.80	-93.80

Days Sales Outstanding	38.70	42.30	46.70	106	57.40	48.90	34.40	31.90	47.40	34.20	53.80	48.20	40.40	37.80	39.00	53.80
Days Inventory	--	--	--	--	--	--	--	--	510	39.70	45.80	301	69.80	204	31.60	45.80
Inventory Turnover	--	--	--	--	--	--	--	--	0.70	9.20	2.00	0.30	1.30	0.40	2.90	2.00

Debt to Revenue	5.00	3.26	1.12	0.57	0.10	1.64	1.51	3.75	0.28	0.46	2.25	0.91	0.96	1.19	2.09	2.25
COGS to Revenue	0.05	0.05	0.06	0.06	0.07	0.09	0.14	0.09	0.06	0.18	0.13	0.09	0.27	0.11	0.26	0.13
Inventory to Revenue	--	--	--	--	--	--	--	--	0.08	0.02	0.07	0.30	0.21	0.26	0.09	0.07
Interest Exp. to Revenue %	-2.73	-7.78	-3.31	6.97	14.33	1.63	-8.03	-12.08	-2.59	-0.96	--	-0.85	-0.87	-1.20	-0.99	--

Asset Turnover	0.10	0.19	0.29	0.24	0.33	0.18	0.05	0.08	0.64	0.55	0.14	0.19	0.16	0.12	0.12	0.14
Buyback Ratio	6.10	5.30	--	177	8.20	78.70	132	4.40	-303	375	6.90	-24.20	397	64.00	21.50	6.90
Income Statement	Annuals (USD $) View: $ %											Quarterly
Fiscal Period	Dec03	Dec04	Dec05	Dec06	Dec07	Dec08	Dec09	Dec10	Dec11	Dec12	TTM	Mar12	Jun12	Sep12	Dec12	Mar13

Revenue	69.14	103	161	216	199	176	102	143	1,411	1,527	1,417	439	418	336	334	328
Cost of Goods Sold	3.13	5.65	10.10	12.17	13.90	15.69	14.20	12.73	80.51	280	283	39.21	114	38.54	87.72	42.74
Gross Profit	66.02	97.07	151	204	185	160	87.69	131	1,330	1,247	1,133	400	304	297	246	286

Selling, General, &Admin. Expense	39.08	42.14	43.99	57.86	84.73	102	130	188	401	437	419	111	118	97.68	110	92.88
Research &Development	200	192	249	372	513	516	550	637	708	806	828	196	197	200	213	218
Earnings Before DDA	-241	-125	-123	-203	-392	-431	-584	-666	149	40.52	-487	100	-2.11	7.52	-65.10	-428

Depreciation, Depletion and Amortization	23.44	29.64	27.29	25.87	27.46	32.20	30.11	30.46	35.04	38.19	40.32	8.56	8.67	8.59	12.37	10.69

Operating Income	-265	-155	-150	-229	-420	-463	-614	-696	114	2.33	-528	91.65	-10.77	-1.07	-77.48	-438
Interest Income/Expense	-1.89	-7.99	-5.33	15.07	28.51	2.86	-8.18	-17.32	-36.57	-14.71	-10.97	-3.74	-3.64	-4.04	-3.30	--
Net Income	-197	-166	-203	-207	-391	-460	-642	-755	29.57	-107	-507	91.59	-64.93	-57.54	-76.15	-308

Earnings per Share ($)	-2.56	-2.12	-2.28	-1.83	-3.03	-3.27	-3.71	-3.77	0.14	-0.50	-2.37	0.43	-0.31	-0.27	-0.36	-1.43
Total Shares Outstanding	77.00	78.57	89.24	113	129	141	173	200	209	212	215	219	211	214	215	215
Balance Sheet	Annuals (USD $) View: $ %											Quarterly
Fiscal Period	Dec03	Dec04	Dec05	Dec06	Dec07	Dec08	Dec09	Dec10	Dec11	Dec12	Latest Q.	Mar12	Jun12	Sep12	Dec12	Mar13

Cash and cash equivalents	583	392	361	705	461	832	1,285	1,031	969	1,321	1,239	981	1,223	1,299	1,321	1,239
Accounts Receivable	7.32	11.89	20.60	62.92	31.32	23.49	9.60	12.53	183	143	194	232	186	140	143	194
Inventory	--	--	--	--	--	--	--	--	112	30.46	21.53	130	87.81	86.28	30.46	21.53
Other Current Assets	3.32	2.50	3.30	3.86	4.66	11.99	12.51	13.10	66.77	94.66	111	93.42	96.55	110	94.66	111
Total Current Assets	594	407	385	771	497	868	1,307	1,057	1,331	1,590	1,566	1,436	1,593	1,635	1,590	1,566

Property, Plant and Equipment	80.08	64.23	54.53	61.54	66.51	68.33	62.28	72.33	133	434	504	170	273	347	434	504
Intangible Assets	--	--	--	--	--	--	545	545	694	694	282	694	694	694	694	282
Other Long Term Assets	50.52	74.52	109	88.64	38.12	44.57	41.38	51.27	45.36	41.60	40.63	44.91	44.50	42.56	41.60	40.63
Total Assets	724	545	549	922	601	980	1,955	1,725	2,204	2,759	2,392	2,346	2,605	2,719	2,759	2,392

Accounts Payable	113	101	65.81	109	127	158	163	179	347	346	339	326	339	365	346	339
Current Portion of Long-Term Debt	4.66	--	--	104	20.00	--	32.07	137	--	28.88	8.30	--	--	--	28.88	8.30
Other Current Liabilities	21.75	52.43	34.44	38.52	52.68	58.93	90.18	159	45.04	57.32	60.74	30.49	40.65	41.25	57.32	60.74
Total Current Liabilities	139	154	100	251	199	217	285	475	392	433	408	357	380	407	433	408

Long-Term Debt	341	335	180	20.00	--	288	122	400	400	668	732	400	400	400	668	732
Other Long-Term Liabilities	51.77	21.27	29.48	145	131	238	452	347	625	659	507	659	787	884	659	507
Total Liabilities	532	510	310	416	330	742	859	1,221	1,417	1,760	1,646	1,415	1,567	1,691	1,760	1,646

Common Stock	0.78	0.81	1.08	1.24	1.31	1.49	1.98	2.02	2.07	2.15	2.16	2.09	2.13	2.14	2.15	2.16
Retained Earnings	-620	-786	-990	-1,196	-1,588	-2,048	-2,690	-3,444	-3,415	-3,522	-3,830	-3,323	-3,388	-3,446	-3,522	-3,830
Additional Paid-In Capital	810	834	1,244	1,702	1,857	2,282	3,785	3,947	4,201	4,519	4,575	4,252	4,424	4,472	4,519	4,575
Total Equity	193	35.44	239	506	271	239	1,096	504	787	999	746	930	1,038	1,028	999	746
Cashflow Statement	Annuals (USD $) View: $ %											Quarterly
Fiscal Period	Dec03	Dec04	Dec05	Dec06	Dec07	Dec08	Dec09	Dec10	Dec11	Dec12	TTM	Mar12	Jun12	Sep12	Dec12	Mar13

Net Income	-197	-166	-203	-207	-391	-460	-642	-755	41.18	-51.14	-452	87.88	-34.47	-26.47	-78.08	-313
Depreciation, Depletion and Amortization	23.44	29.64	27.29	25.87	27.46	32.20	30.11	30.46	35.04	38.19	40.32	8.56	8.67	8.59	12.37	10.69
Cash Flow from Others	5.71	-5.55	4.07	159	111	201	184	88.73	67.52	281	610	-93.52	144	124	106	236
Cash Flow from Operations	-168	-142	-172	-22.48	-252	-226	-428	-635	144	268	199	2.92	118	106	40.56	-65.78

Investment for Property, Plant & Equipement	-17.35	-12.50	-16.96	-32.42	-32.42	-32.18	-23.50	-38.05	-94.60	-71.14	-81.59	-6.16	-15.54	-21.40	-28.05	-16.61
Cash Flow from Acquisitions	--	--	--	--	--	--	-87.42	--	--	--	--	--	--	--	--	--
Cash Flow from Investing	120	107	-1.73	-208	405	-361	-509	7.30	212	-426	-232	-232	-70.04	-131	7.16	-37.60

Net Issuance of Stock	11.96	8.74	--	366	31.97	362	849	33.43	125	192	192	21.30	137	16.95	16.77	21.67
Net Issuance of Debt	25.51	-12.56	198	--	-42.10	259	150	392	-250	--	--	--	--	-8.68	8.68	--
Other Financing	0.00	-4.81	-0.14	-0.17	-0.05	0.00	--	0.00	0.90	-19.52	-47.55	0.23	0.99	-0.12	-20.61	-27.81
Cash Flow from Financing	37.47	-8.63	197	366	-10.19	621	999	425	-124	172	145	21.53	138	8.15	4.84	-6.14

Net Change in Cash	-9.94	-43.15	23.04	135	142	33.45	57.54	-203	232	14.09	111	-207	186	-17.18	52.52	-110

Free Cash Flow	-185	-155	-189	-54.89	-285	-259	-451	-673	49.14	197	118	-3.24	103	84.57	12.51	-82.39
Valuation Ratios (Daily)	Annuals											Quarterly
Fiscal Period	Dec03	Dec04	Dec05	Dec06	Dec07	Dec08	Dec09	Dec10	Dec11	Dec12	Latest Q.	Mar12	Jun12	Sep12	Dec12	Mar13

PE Ratio(ttm)
Price to Tangible Book
Price-to-Free-Cash-Flow ratio
PS Ratio
EV-to-Revenue
EV-to-EBITDA
EV-to-EBIT
Earnings Yield (Joel Greenblatt)
Forward Rate of Return
Shiller PE Ratio
Valuation and Quality	Annuals											Quarterly
Fiscal Period	Dec03	Dec04	Dec05	Dec06	Dec07	Dec08	Dec09	Dec10	Dec11	Dec12	Latest Q.	Mar12	Jun12	Sep12	Dec12	Mar13

Market Cap
Enterprise Value
Month End Stock Price
Net Cash (per share)
Net Current Asset Value (per share)
DCF (per share)
Median PS (per share)
Peter Lynch Fair Value (per share)
Graham Number (per share)
Altman Z-Score
Piotroski F-Score
Beneish M-Score

Switch to Another Stock:

VRTX Quarterly/Annuals Reports

VRTX: 10-Q - VERTEX PHARMACEUTICALS INC / MA (0000875320) (Filer): (10-Q) - 2012-11-06
VRTX: 10-Q/A - VERTEX PHARMACEUTICALS INC / MA (0000875320) (Filer): (10-Q/A) - 2012-09-07
VRTX: 10-Q - VERTEX PHARMACEUTICALS INC / MA (0000875320) (Filer): (10-Q) - 2012-08-08
VRTX: 10-Q - VERTEX PHARMACEUTICALS INC / MA (0000875320) (Filer): (10-Q) - 2012-05-10
VRTX: 10-Q/A - VERTEX PHARMACEUTICALS INC / MA (0000875320) (Filer): (10-Q/A) - 2012-03-02

GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names

Home About Jobs Advertise Site Map Term of Use Privacy Policy RSS Email Alerts Affiliate Program FAQ Contact Us
Disclaimers: GuruFocus.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The gurus may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.

FocusBar

Home

Premium Membership

Value Screens

Model Portfolios

Guru Stocks

Market Valuation

By Country

Articles

Submit Articles

VRTX Quarterly/Annuals Reports